Semax: Nootropic Peptide Research, BDNF & Cognitive Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Semax?

Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH), specifically derived from the ACTH(4-10) fragment. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro, which corresponds to the ACTH(4-7) core with an added C-terminal Pro-Gly-Pro tripeptide extension designed to enhance metabolic stability and extend the peptide’s half-life.

Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s by a team led by Professors Nikolai Myasoedov and Isaak Ashmarin, Semax was originally investigated as a nootropic — a cognitive-enhancing agent — and later explored for neuroprotective applications in stroke and brain injury. It has been approved as a pharmaceutical product in Russia and several CIS countries since 1996, where it is available as a nasal spray formulation for cognitive enhancement and stroke recovery.

What distinguishes Semax from the parent ACTH molecule is the deliberate elimination of hormonal activity. While full-length ACTH stimulates cortisol production through the MC2R receptor in the adrenal glands, Semax does not activate this receptor at research-relevant doses and does not cause adrenal stimulation or cortisol elevation. Instead, its biological activities are mediated through melanocortin receptor subtypes (MC3R, MC4R, and MC5R) and through receptor-independent mechanisms including direct neurotrophic factor modulation.

How Semax Works: Mechanism of Action

Research has identified multiple mechanisms through which Semax influences neurological function:

• BDNF upregulation — Brain-derived neurotrophic factor (BDNF) is a critical protein for neuron survival, synaptic plasticity, and memory formation. Semax has been consistently shown to upregulate BDNF expression in the hippocampus, prefrontal cortex, and other brain regions. A 2010 study published in Neuroscience Letters documented a 1.4 to 1.8-fold increase in BDNF mRNA expression in rat hippocampus following Semax administration. This BDNF upregulation is considered the primary mechanism underlying Semax’s nootropic effects.
• Neurotrophic factor cascade — Beyond BDNF, Semax has been shown to modulate the expression of nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3). This broad neurotrophic response suggests that Semax activates upstream regulatory mechanisms that influence multiple trophic factors simultaneously rather than acting on a single pathway.
• Melanocortin receptor signaling — Semax acts as a partial agonist at MC4R receptors in the central nervous system. MC4R activation in the hippocampus and cortex has been associated with enhanced synaptic plasticity, long-term potentiation (LTP), and memory consolidation. The MC4R pathway also intersects with dopaminergic and serotonergic signaling, potentially explaining Semax’s reported effects on mood and motivation.
• Gene expression modulation — Transcriptomic studies using microarray analysis have revealed that Semax modulates the expression of hundreds of genes in the brain, with functional clusters related to neurotransmission, synaptic plasticity, immune response, and vascular function. A 2016 study identified 1,239 differentially expressed genes in the rat frontal cortex following Semax treatment, including upregulation of neuroprotective genes and downregulation of pro-apoptotic factors.
• Dopaminergic and serotonergic modulation — Research has documented that Semax influences dopamine and serotonin turnover in the brain, with effects on both synthesis and metabolism of these neurotransmitters. Studies have reported increased dopamine and serotonin levels in the striatum and nucleus accumbens following Semax administration.
• Anti-inflammatory neuroprotection — Semax has demonstrated anti-inflammatory effects in the central nervous system, including reduced microglial activation, decreased pro-inflammatory cytokine expression, and modulation of the NF-κB inflammatory pathway in brain tissue.

Cognitive Enhancement Research

Learning and Memory Studies

Semax has been extensively investigated in rodent models of learning and memory. Key findings include:

• Morris water maze — Semax-treated rats showed improved spatial learning acquisition and memory retention in the Morris water maze paradigm, a standard test of hippocampal-dependent spatial memory
• Passive avoidance — Enhanced passive avoidance retention, indicating improved fear-associated memory consolidation
• Novel object recognition — Improved performance on novel object recognition tasks, suggesting enhanced declarative memory
• Radial arm maze — Improved working memory performance in the radial arm maze, a test of executive function and spatial working memory

These cognitive effects have been correlated with increased hippocampal BDNF levels and enhanced long-term potentiation (LTP) at hippocampal synapses — the cellular mechanism believed to underlie learning and memory formation.

Russian Clinical Experience

In Russia, Semax has been used clinically since 1996 as a 1% nasal spray (3 mg/mL) indicated for cognitive dysfunction and cerebrovascular insufficiency. While much of the Russian clinical data has been published in Russian-language journals (limiting accessibility to the Western research community), key findings reported from clinical use include:

• Improvements in attention, working memory, and mental processing speed in patients with cognitive impairment
• Enhanced cognitive recovery following cerebrovascular events
• Favorable safety profile with over two decades of clinical use

It should be noted that Russian pharmaceutical approval standards differ from FDA requirements, and the clinical evidence base does not include the large-scale, phase III randomized controlled trials typical of Western drug development.

Neuroprotection and Stroke Research

Ischemic Stroke Models

Neuroprotection in cerebral ischemia is one of the most extensively studied applications of Semax. In middle cerebral artery occlusion (MCAO) models of ischemic stroke in rats, Semax administration has been associated with:

• Reduced infarct volume (brain tissue damage) — multiple studies report 30–50% reductions
• Improved neurological deficit scores on standardized behavioral assessments
• Reduced cerebral edema
• Upregulation of neuroprotective gene programs, including anti-apoptotic factors (Bcl-2) and antioxidant enzymes
• Modulation of the neuroinflammatory response in the ischemic penumbra

Optic Nerve Neuroprotection

An intriguing extension of Semax’s neuroprotective research involves the optic nerve. Studies have investigated Semax in models of optic nerve damage (including ischemic and toxic models), reporting protective effects on retinal ganglion cells and improved visual function parameters. This application leverages both Semax’s neurotrophic factor upregulation and its anti-inflammatory mechanisms.

Gene Expression in Ischemia

A 2015 transcriptomic study examined the effect of Semax on gene expression in ischemic brain tissue, comparing the transcriptomes of untreated ischemic tissue, Semax-treated ischemic tissue, and normal brain tissue. The study found that Semax treatment partially reversed the gene expression changes caused by ischemia — shifting the transcriptomic profile of damaged tissue back toward the normal pattern. This “transcriptomic normalization” involved hundreds of genes and suggested that Semax acts broadly to restore gene regulatory networks disrupted by ischemic injury.

Semax and Selank: Complementary Nootropic Peptides

Semax is frequently discussed alongside Selank, another Russian-developed neuropeptide. While both are classified as nootropics, they operate through distinct mechanisms:

Parameter	Semax	Selank
Parent molecule	ACTH(4-10)	Tuftsin (Thr-Lys-Pro-Arg)
Primary mechanism	BDNF upregulation, melanocortin signaling	GABA modulation, enkephalin metabolism
Primary effects	Cognitive enhancement, neuroprotection	Anxiolytic, immune modulation
Neurotransmitter focus	Dopamine, serotonin, BDNF	GABA, serotonin, enkephalins
Clinical approval	Russia (1996) — cognitive, stroke	Russia (2009) — anxiety
Route	Intranasal	Intranasal

The complementary profiles of Semax (primarily cognitive and neuroprotective) and Selank (primarily anxiolytic and immune-modulatory) have led to research interest in combining the two peptides, though published combination studies are limited.

Immune Function Research

While primarily studied for neurological effects, Semax has also demonstrated immunomodulatory properties. Research has documented:

• Modulation of immune gene expression profiles in brain tissue
• Enhanced expression of immune-related chemokines and their receptors
• Effects on inflammatory mediator balance in both central and peripheral compartments

The immune effects are likely mediated through melanocortin receptor signaling, as the melanocortin system is a well-established regulator of immune and inflammatory responses.

Modified Semax Variants

Russian researchers have developed several modified versions of Semax with enhanced properties:

• N-acetyl Semax (NASA) — N-terminal acetylation enhances metabolic stability and potentially increases blood-brain barrier penetration. This variant is commonly available from research suppliers.
• N-acetyl Semax amidate (NASA-amidate) — Combined N-terminal acetylation and C-terminal amidation provide further stability enhancement.
• Semax 0.1% and 1% — Different concentration formulations used in Russian clinical practice, with the 1% formulation used for more severe cognitive deficits.

Dosing in Research Models

Research Context	Dose	Route	Duration
Russian clinical (cognitive)	200–600 μg/day	Intranasal	10–14 day courses
Russian clinical (stroke)	6,000–12,000 μg/day	Intranasal	5–14 days acute
Rodent cognitive studies	50–600 μg/kg	Intranasal or IP	7–14 days
Rodent stroke models	100–300 μg/kg	IP injection	Single or 3–7 days
BDNF expression studies	50–100 μg/kg	IP injection	Single dose to 7 days

Reconstitution and Handling

• Storage — Lyophilized Semax at -20°C for long-term stability
• Reconstitution — Reconstitute with sterile bacteriostatic water. For intranasal research, reconstitute to the desired concentration (typically 1–3 mg/mL).
• Stability — Reconstituted solution stable approximately 20–30 days at 2–8°C. The Pro-Gly-Pro extension provides enhanced proteolytic resistance compared to the native ACTH fragment.
• Intranasal delivery — For research protocols using intranasal administration, sterile nasal spray vials are recommended. The nasal mucosa provides direct access to the olfactory nerve pathway, allowing CNS delivery that bypasses the blood-brain barrier.

Safety Profile

Semax has accumulated the most extensive clinical safety data of any research nootropic peptide, based on over two decades of pharmaceutical use in Russia:

• No hormonal effects — Unlike the parent ACTH molecule, Semax does not stimulate cortisol production or cause adrenal axis activation at research doses
• No addiction or tolerance — Russian clinical data has not documented dependence or tolerance development with repeated use
• No withdrawal effects — Discontinuation after chronic use has not been associated with rebound cognitive decline or withdrawal symptoms
• Minimal reported side effects — The most commonly reported effects in clinical use include mild nasal irritation (from intranasal delivery) and occasional mild headache
• No cardiovascular effects — Blood pressure, heart rate, and other cardiovascular parameters remain stable with Semax administration

Current Limitations and Future Directions

• Language barrier in literature — A significant portion of Semax clinical data is published in Russian-language journals, limiting its accessibility to the international research community and making independent evaluation difficult
• No Western clinical trials — Semax has not been evaluated in FDA-standard clinical trials, which limits its acceptance in Western evidence-based frameworks
• Mechanism complexity — The multi-target nature of Semax’s action (melanocortin receptors, neurotrophic factors, gene expression) makes it challenging to attribute specific clinical effects to individual mechanisms
• Peptide delivery challenges — While intranasal delivery provides reasonable CNS access, developing standardized research formulations for consistent dosing remains technically challenging
• Limited comparative studies — Head-to-head comparisons with established nootropics or neuroprotective agents are scarce

Future research priorities include Western-standard clinical trials (particularly for stroke neuroprotection, where the medical need is acute), mechanistic studies using modern neuroscience tools (optogenetics, CRISPR), expanded transcriptomic analysis, and development of modified analogs with improved pharmacokinetic properties.

Summary

Semax is a synthetic ACTH(4-10) analog that has been the subject of extensive research as a nootropic and neuroprotective peptide. Its mechanisms center on BDNF upregulation, melanocortin receptor signaling, and broad-spectrum gene expression modulation in the central nervous system. With over two decades of clinical use in Russia and a substantial preclinical literature documenting cognitive enhancement and neuroprotective effects in multiple models, Semax represents one of the most well-characterized nootropic peptides available for research. The primary limitation remains the absence of Western-standard clinical trial data, which represents a critical gap for broader scientific acceptance.

View Semax in our research catalog. For complementary nootropic research, see Selank. Other cognitive research peptides: Pinealon, Cortagen, and DSIP.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Dolotov et al.	2006	In Vivo	Semax regulates BDNF and trkB expression in rat hippocampus	PMID 16996037
Derkach et al.	2024	In Vivo	Semax and Pro-Gly-Pro activate neurotrophin gene transcription after cerebral ischemia	PMC11498467
Dergunova et al.	2014	In Vivo	Genome-wide transcriptional analysis of Semax in rat brain focal ischemia	PMC3987924
Ivanikov et al.	2022	In Vitro	Semax affects copper-induced amyloid-beta aggregation and amyloid formation	PMC8855339
Dmitrieva et al.	2021	In Vivo	Brain protein expression profile confirms protective effect of Semax in ischemia-reperfusion	PMC8226508
Filippenkov et al.	2020	In Vivo	Novel insights into protective properties of Semax at transcriptome level	PMC7350263
Glazova et al.	2006	In Vivo	Semax binds specifically and increases BDNF protein in rat basal forebrain	PMID 16635254
Ashmarin et al.	1997	Review	Nootropic ACTH analog 4-10 Semax — 15 years of design and study	PMID 9173745

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.